The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 354:1645-1647 April 13, 2006 Number 15
NextNext

Deaths from Clostridium sordellii after Medical Abortion

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Greene, M. F.
-Related Article
by Fischer, M.
-PubMed Citation
To the Editor: Since its approval in France in 1988, a regimen of mifepristone (RU 486) and a prostaglandin has been used to terminate more than 1.2 million pregnancies of up to seven weeks of gestation. Most women have received oral mifepristone (at a dose of 600 mg), followed by oral misoprostol (at 400 or 800 µg).1,2 Success rates have exceeded 95 percent, and uterine infection (endometritis) has been rare (≤1 percent), less than the rate of infection after surgical abortion.3 No case of Clostridium sordellii has been reported. Mifepristone has also appeared to be safe when it has . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.